Document is current
Any future updates will be listed below
-
Authors
Usuki, Kensuke
Handa, Hiroshi
Choi, Ilseung
Yamauchi, Takahiro
Iida, Hiroatsu
Hata, Tomoko
Ohwada, Shoichi
Okudaira, Noriko
Nakamura, Kota
Sakajiri, Sakura
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct02675478 at ClinicalTrials.govDocuments that mention this clinical trial
Safety and pharmacokinetics of quizartinib in Japanese patients with relapsed or refractory acute myeloid leukemia in a phase 1 study
https://doi.org/10.1007/s12185-019-02709-8
-
Funding
Funding for this research was provided by:
Daiichi Sankyo Co., Ltd.
- License Information
-
More Information
Article History
Received: 28 March 2019
Revised: 17 July 2019
Accepted: 17 July 2019
First Online: 29 July 2019
Compliance with ethical standards
:
: KU has received honoraria and lecture fees from Novartis and research funding from Fujimoto, Astellas, Otsuka, Sumitomo Dainippon, Kyowa Hakko Kirin, GlaxoSmithKline, Sanofi, Shire, SymBio, Celgene, Daiichi Sankyo, Boehringer Ingelheim, Pfizer, and Janssen, and speakers bureau from Novartis, Ono, Takeda, Chugai, Nippon Shinyaku, Mochida, MSD, Celgene, Sumitomo Dainippon, and Pfizer. HH has received honoraria, lecture fees, and research funding from Daiichi Sankyo. TY has received research funding from Otsuka, Astellas, AbbVie, Boehringer Ingelheim, and Solasia and subsidies/donations from Taisho Toyama, Chugai, Teijin Pharma, Fuji Yakuhin, Bristol-Myers, Ono, Pfizer, and Japan Atherosclerosis Research Foundation. SO, and KN are employees of Daiichi Sankyo. NO was an employee of Daiichi Sankyo and is currently an employee of Certara. SS was an employee of Daiichi Sankyo at the time of this study. HI has received research funding from Chugai. IC and TH have no conflicts of interest to declare.
